Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12890856 | 0.91 | HRH3 (0.43) | HRH3KCNH2 | |
| SCHEMBL25480233 | 0.89 | HRH3 (0.44) | HRH3KCNH2 | |
| SCHEMBL22565447 | 0.86 | HRH3 (0.38) | HRH3KCNH2 | |
| SCHEMBL24501875 | 0.81 | HRH3 (0.40) | HRH3KCNH2 | |
| SCHEMBL8364993 | 0.81 | HRH3 (0.40) | HRH3KCNH2ACHESIGMAR1 | |
| SCHEMBL24671761 | 0.81 | NCF1 (0.46) | HRH3KCNH2ACHE | |
| SCHEMBL105496 | 0.79 | ALDH1A1 (0.41) | HRH3KCNH2ACHESIGMAR1 | |
| SCHEMBL4034418 | 0.78 | HRH3 (0.41) | HRH3KCNH2SIGMAR1 | |
| SCHEMBL330763 | 0.76 | ACHE (0.33) | ACHE | |
| SCHEMBL23484949 | 0.76 | ACHE (0.60) | HRH3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| WO-2021055295-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398117-A1 | 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide Derivatives | PAH, PKD1, REN | HRH3 531/4885KCNH2 1418/4885OPRK1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.